ADAM17 knockout anti-CD70 CAR NK-cell therapy (Nkarta Therapeutics/Adicet Bio)

N/A

Report date: 2023/12/04 17:53:21

Base Information

Drug NameADAM17 knockout anti-CD70 CAR NK-cell therapy (Nkarta Therapeutics/Adicet Bio)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsAnti-CD70
TargetsCD70 antigen
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAdicet Bio IncNkarta Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesNkarta TherapeuticsAdicet Bio Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A